Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucose Monitoring, Insulin Delivery May 30 | 2019FENIX Analysis: Devices Promotional Materials Post-AACE 2019Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery May 23 | 2019Medtronic CY Q1 '19 (FY Q4 '19) Earnings UpdatePurchase Blast
$599
Posted in: Glucagon, Insulin Delivery May 22 | 2019Zealand/Beta Bionics Initiate iLet In-home Closed-Loop TrialPurchase Blast
$599
Posted in: Bolus Insulin May 22 | 2019Lilly's Lispro Authorized Generic Now Available in US PharmaciesPurchase Blast
Free
Posted in: SGLT2i May 22 | 2019CREDENCE Priority Review for Invokana; PDUFA Projected in Late September 2019Access Free Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA + Basal May 21 | 2019FENIX Analysis: Insulin Promotional Materials Post-AACE 2019Purchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery May 21 | 2019Glooko Appoints Mark Clements as CMOPurchase Blast
Free
Posted in: Glucose Monitoring May 21 | 2019Lifescan Enters CGM Market with New Partnership; Ty Lee Returns to LifescanAccess Free Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery May 17 | 2019FDA Warns Against DIY Closed-Loop SystemsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA May 17 | 2019New Tirzepatide vs. Semaglutide Ph1 T2DM Clamp Study; Ph3 SURPASS-1 Monotherapy Trial InitiatedPurchase Blast$599
Posted in: SGLT2i May 16 | 2019FENIX Analysis: SGLT2i Promotional Materials Post-AACE 2019Purchase Blast
$599
Posted in: Dual/triple agonist, Glucagon May 16 | 2019Zealand Q1 '19 Earnings UpdatePurchase Blast
$599
Posted in: Dual/triple agonist, SGLT2i May 15 | 2019JNJ 2019 Pharmaceutical Business ReviewPurchase Blast
Free
Posted in: Dual/triple agonist, GLP-1RA May 15 | 2019Lilly oral dual agonist comments @ BAMLAccess Free Blast
$599
Posted in: Glucagon May 14 | 2019Zealand's Dasiglucagon Filing Delayed; Positive Ph3 Dasiglucagon Topline ResultsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA, GLP-1RA + Basal, Insulin Delivery May 13 | 2019FDA Issues Final Guidance on Biosimilar InterchangeabilityPurchase Blast$599
Posted in: GLP-1RA May 13 | 2019FENIX Analysis: GLP-1RA Promotional Materials Post-AACE 2019Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, DPP-IVi, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucagon, Glucose Monitoring, Insulin Delivery, SGLT2i May 10 | 2019ADA 2019 Abstract and Session Titles AvailablePurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery May 09 | 2019Senseonics, BD, and Xeris Q1 '19 Earnings UpdatesPurchase Blast